logo
Plus   Neg
Share
Email

Genentech: FDA Grants Priority Review For Rituxan In Pediatric Indication

Genentech, a member of the Roche Group (RHHBY), said the FDA has granted priority review for Rituxan (rituximab), in combination with glucocorticoids, for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis in children above two years of age. Rituxan is currently approved for the treatment of four autoimmune indications.

The FDA accepted the company's sBLA which was based on data from the PePRS study, a Phase IIa, global study investigating intravenous Rituxan in 25 patients between six and 17 years of age.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A survey has shown that while a majority of Americans want to buy a car that contributes substantially to the U.S. economy amid rising trade tensions, most of the "American-made" cars are actually produced by foreign automakers. According to Cars.com's 2019 American-Made Index, the most 'American-made' vehicle in 2019 is the Jeep Cherokee. Streaming giant Netflix Inc. (NFXL) is set to lose the right to stream "The Office," one of the most popular TV show on the service. NBC Universal announced it is taking back the popular TV show for its own streaming platform, beginning January 2021. "We're sad that NBC has decided to take The... Chinese smartphone maker Xiaomi has announced that its recently launched Mi Band 4 crossed 1 million units sales in just eight days. Xiaomi's Director of Product Management Donovan Sung tweeted this news as he thanked Mi fans for the achievement. "Sharing some great news with our global Mi Fans....
Follow RTT